Pharmaceutical company Pfizer expects to produce 80 million doses of its experimental antiviral drug against Covid-19, more than its previous forecast of $ 50 million, CEO Albert Burla said today in an interview with CNBC.
Earlier this month, Pfizer announced that it hoped to produce 180,000 doses by the end of the year and at least 50 million doses by the end of next year, of which 21 million in the first half of 2022.
“Right now we can commit to 80 million doses … thanks to our plant,” Burla said.
Burla also said he was convinced the drug, branded Paxlovid, would not be affected by the ‘Micron’ variant.
He added that the pharmaceutical industry will know more details about the new variant in the coming weeks.
Pfizer applied for emergency approval of Paxlovid last week after reporting evidence that it is 89% effective in preventing illness or death in high-risk individuals.
Follow Skai.gr on Google News
and be the first to know all the news
.
